Compare COIN & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COIN | NTRA |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0B | 39.1B |
| IPO Year | 2021 | 2015 |
| Metric | COIN | NTRA |
|---|---|---|
| Price | $167.32 | $258.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 30 | 15 |
| Target Price | ★ $304.12 | $259.07 |
| AVG Volume (30 Days) | ★ 6.2M | 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,181,325,000.00 | $210,939,000.00 |
| Revenue This Year | $3.76 | $18.08 |
| Revenue Next Year | $17.98 | $19.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9.40 | N/A |
| 52 Week Low | $139.18 | $131.81 |
| 52 Week High | $402.16 | $288.04 |
| Indicator | COIN | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.58 | 50.49 |
| Support Level | $156.72 | $186.96 |
| Resistance Level | $174.79 | $288.04 |
| Average True Range (ATR) | 7.90 | 10.42 |
| MACD | 1.03 | -3.74 |
| Stochastic Oscillator | 50.71 | 15.47 |
Founded in 2012, Coinbase is the leading cryptocurrency exchange platform in the United States. The company intends to be the safe and regulation-compliant point of entry for retail investors and institutions into the cryptocurrency economy. Users can establish an account directly with the firm, instead of using an intermediary, and many choose to allow Coinbase to act as a custodian for their cryptocurrency, giving the company breadth beyond that of a traditional financial exchange. While the company still generates the majority of its revenue from transaction fees charged to its retail customers, Coinbase uses internal investment and acquisitions to expand into adjacent businesses, such as prime brokerage and data analytics.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.